Oncology News | pharmaphorum

News

Dynavax cuts staff and cancer R&D, focuses on vaccine

US biotech Dynavax has announced staff cutbacks after deciding to focus on its vaccine business, while winding down its immune-oncology research.

News

Amgen offers $167m for drug discovery biotech Nuevolution

Amgen has agreed to buy Swedish biotech Nuevolution for around $167 million to boost its drug pipeline after an R&D collaboration showed promise.

News

Lilly moves Crohn's drug into phase 3, faces safety setback ...

Eli Lilly has had a mixed few days, posting promising trial results for mid-stage Crohn’s disease drug mirikizumab, undercutting a key insulin from Sanofi in the US, but facing safety conce

News

Merck & Co to buy cancer biotech Peloton for $2.2bn

Merck & Co is to buy the privately-held biotech Peloton for up to $2.2 billion, adding further oncology drugs to its pipeline as it searches for successors to cancer blockbuster Keytrud

News

Merck & Co's Keytruda fails in triple negative breast cancer...

Most of the time, Merck & Co’s Keytruda (pembrolizumab) has been a consistent performer across a range of cancers – but it has produced an uncharacteristic failure in tough to treat tri

News

Reitsberger Hof Originalbild unter: http://xaver.fotograf.de/photo/5803d868-7d30-46c9-9bef-33690a5581f6

Morphosys to take on CAR-Ts in NHL with promising antibody

Germany’s Morphosys has announced results from its combination therapy of an experimental antibody and Celgene’s Revlimid in a common form of non-Hodgkin lymphoma, saying that the phase 2 t

Dynavax cuts staff and cancer R&D, focuses on vaccine

Amgen offers $167m for drug discovery biotech Nuevolution

Lilly moves Crohn's drug into phase 3, faces safety setback ...

Merck & Co to buy cancer biotech Peloton for $2.2bn

Merck & Co's Keytruda fails in triple negative breast cancer...

Morphosys to take on CAR-Ts in NHL with promising antibody

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks